<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Med</journal-id><journal-title>The Journal of Experimental Medicine</journal-title><issn pub-type="ppub">0022-1007</issn><issn pub-type="epub">1540-9538</issn><publisher><publisher-name>The Rockefeller University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10049951</article-id><article-id pub-id-type="pmc">2192952</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brief Definitive Reports</subject></subj-group></article-categories><title-group><article-title>Melanoma Cells Present a MAGE-3 Epitope to CD4<sup>&#x0002b;</sup>  Cytotoxic T Cells in Association with Histocompatibility  Leukocyte Antigen DR11 </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Manici</surname><given-names>Simona</given-names></name><xref ref-type="aff" rid="N0x35a1910N0x3f1f9a8">&#x0002a;</xref><xref ref-type="aff" rid="N0x35a1910N0x3f1f9a8">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Sturniolo</surname><given-names>Tiziana</given-names></name><xref ref-type="aff" rid="N0x35a1910N0x3f1f9a8">&#x000b6;</xref></contrib><contrib contrib-type="author"><name><surname>Imro</surname><given-names>Maria Adele</given-names></name><xref ref-type="aff" rid="N0x35a1910N0x3f1f9a8">&#x0002a;</xref><xref ref-type="aff" rid="N0x35a1910N0x3f1f9a8">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Hammer</surname><given-names>Juergen</given-names></name><xref ref-type="aff" rid="N0x35a1910N0x3f1f9a8">&#x0002a;&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Sinigaglia</surname><given-names>Francesco</given-names></name><xref ref-type="aff" rid="N0x35a1910N0x3f1f9a8">&#x000b6;</xref></contrib><contrib contrib-type="author"><name><surname>Noppen</surname><given-names>Christoph</given-names></name><xref ref-type="aff" rid="N0x35a1910N0x3f1f9a8">&#x02020;&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Spagnoli</surname><given-names>Giulio</given-names></name><xref ref-type="aff" rid="N0x35a1910N0x3f1f9a8">&#x02020;&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Mazzi</surname><given-names>Benedetta</given-names></name><xref ref-type="aff" rid="N0x35a1910N0x3f1f9a8">&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Bellone</surname><given-names>Matteo</given-names></name><xref ref-type="aff" rid="N0x35a1910N0x3f1f9a8">&#x0002a;</xref><xref ref-type="aff" rid="N0x35a1910N0x3f1f9a8">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Dellabona</surname><given-names>Paolo</given-names></name><xref ref-type="aff" rid="N0x35a1910N0x3f1f9a8">&#x02021;</xref><xref ref-type="aff" rid="N0x35a1910N0x3f1f9a8">&#x02016;</xref></contrib><contrib contrib-type="author"><name><surname>Protti</surname><given-names>Maria Pia</given-names></name><xref ref-type="aff" rid="N0x35a1910N0x3f1f9a8">&#x0002a;</xref><xref ref-type="aff" rid="N0x35a1910N0x3f1f9a8">&#x02021;</xref></contrib></contrib-group><aff id="N0x35a1910N0x3f1f9a8">From the <label>&#x0002a;</label>Laboratory of &#x02009;Tumor Immunology, the <label>&#x02021;</label>Cancer Immunotherapy and Gene Therapy  Program, and the <label>&#x000a7;</label>Laboratory of Molecular Tissue Typing and <label>&#x02016;</label>Immunochemistry Unit, Department of  Biology and Technology (DIBIT), Scientific Institute H. San Raffaele, 20132 Milan, Italy; <label>&#x000b6;</label>Roche  Milano Ricerche, 20132 Milan, Italy; <label>&#x0002a;&#x0002a;</label>Roche Discovery Technologies, Hoffman-La Roche, Inc.,  Nutley, New Jersey 07110; and <label>&#x02020;&#x02020;</label>Departement Chirurgie, Kantonsspital, CH-4031 Basel,  Switzerland</aff><author-notes><fn><p>Address correspondence to Maria Pia Protti, Laboratory of Tumor Immunology, Scientific Institute H. San  Raffaele, Via Olgettina 60, 20132 Milan, Italy. Phone: 39-2-2643-2612; Fax: 39-2-2643-2611; E-mail:  <email>m.protti&#x00040;hsr.it</email></p></fn></author-notes><pub-date pub-type="ppub"><day>1</day><month>3</month><year>1999</year></pub-date><volume>189</volume><issue>5</issue><fpage>871</fpage><lpage>876</lpage><history><date date-type="received"><day>10</day><month>11</month><year>1998</year></date><date date-type="rev-recd"><day>15</day><month>12</month><year>1998</year></date></history><copyright-year>1999</copyright-year><abstract><p>In this study we used TEPITOPE, a new epitope prediction software, to identify sequence segments on the MAGE-3 protein with promiscuous binding to histocompatibility leukocyte antigen (HLA)-DR molecules. Synthetic peptides corresponding to the identified sequences were  synthesized and used to propagate CD4<sup>&#x0002b;</sup> T cells from the blood of a healthy donor. CD4<sup>&#x0002b;</sup> T  cells strongly recognized MAGE-3<sub>281&#x02013;295</sub> and, to a lesser extent, MAGE-3<sub>141&#x02013;155</sub> and MAGE-3<sub>146&#x02013;160</sub>. Moreover, CD4<sup>&#x0002b;</sup> T cells proliferated in the presence of recombinant MAGE-3 after  processing and presentation by autologous antigen presenting cells, demonstrating that the  MAGE-3 epitopes recognized are naturally processed. CD4<sup>&#x0002b;</sup> T cells, mostly of the T helper 1  type, showed specific lytic activity against HLA-DR11/MAGE-3&#x02013;positive melanoma cells.  Cold target inhibition experiments demonstrated indeed that the CD4<sup>&#x0002b;</sup> T cells recognized  MAGE-3<sub>281&#x02013;295</sub> in association with HLA-DR11 on melanoma cells. This is the first evidence  that a tumor-specific shared antigen forms CD4<sup>&#x0002b;</sup> T cell epitopes. Furthermore, we validated  the use of algorithms for the prediction of promiscuous CD4<sup>&#x0002b;</sup> T cell epitopes, thus opening  the possibility of wide application to other tumor-associated antigens. These results have direct  implications for cancer immunotherapy in the design of peptide-based vaccines with tumor-specific CD4<sup>&#x0002b;</sup> T cell epitopes.</p></abstract><kwd-group><kwd>MAGE-3</kwd><kwd>CD4<sup>&#x0002b;</sup> epitopes</kwd><kwd>melanoma</kwd><kwd>tumor vaccines</kwd><kwd>adoptive  immunotherapy</kwd></kwd-group></article-meta></front><body><p>The importance of CD4<sup>&#x0002b;</sup> T lymphocytes in antitumor  immunity has been clearly demonstrated in animal  models. CD4<sup>&#x0002b;</sup> T cells exert helper activity for the induction and maintenance of antitumor CD8<sup>&#x0002b;</sup> T cells (<xref ref-type="bibr" rid="B1">1</xref>&#x02013;<xref ref-type="bibr" rid="B7">7</xref>), but  they may also have an effector function either by indirect  mechanism against MHC class II&#x02013;negative tumors, via macrophages activation (for a review, see reference <xref ref-type="bibr" rid="B1">1</xref>), or by direct mechanism against MHC class II&#x02013;positive tumors (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>).</p><p>Recently, the requirement of cognate CD4<sup>&#x0002b;</sup> T cell help  for optimal induction of antitumor CD8<sup>&#x0002b;</sup> CTLs was demonstrated (<xref ref-type="bibr" rid="B8">8</xref>). Vaccination with a specific viral T helper  epitope, but not with an unrelated T helper epitope, resulted in protective immunity against MHC class II&#x02013;negative, virus-induced tumor cells. Moreover, simultaneous  vaccination with the tumor-specific T helper and CTL  epitopes resulted in strong synergistic protection.</p><p>In humans, evidence for a role of CD4<sup>&#x0002b;</sup> T cells in antitumor immunity comes from the study of tumor-infiltrating lymphocytes, which revealed the presence of both  CD8<sup>&#x0002b;</sup> and CD4<sup>&#x0002b;</sup> T cells at the tumor site (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>), and from  detection in the sera of neoplastic patients of antibodies directed against tumor antigens (for a review, see reference  <xref ref-type="bibr" rid="B11">11</xref>). However, in recent years research on T cell immunity  against human tumors has focused mainly on identification  of CD8<sup>&#x0002b;</sup> HLA class I&#x02013;restricted CTL responses. To date  tyrosinase, a tissue-specific antigen expressed in normal and  neoplastic cells of melanocytic lineage, is the only melanoma-associated antigen demonstrated as a specific target  for CD4<sup>&#x0002b;</sup> melanoma-reactive T cells (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>) and for  which CD4<sup>&#x0002b;</sup> T cell epitopes have been identified (<xref ref-type="bibr" rid="B14">14</xref>).</p><p>Characterization of the CD4<sup>&#x0002b;</sup> T cell epitope repertoire  on other tumor-associated antigens, especially those that  are tumor-specific and shared among tumors of several histotypes (for a review, see reference <xref ref-type="bibr" rid="B15">15</xref>), would contribute  decisively to improve the efficacy of peptide-based immunization protocols in neoplastic patients.</p><p>MAGE-3 is a tumor-specific antigen encoded by a gene  expressed in a high proportion of melanomas and in several  other tumor histotypes (head and neck squamous cell carcinomas, bladder carcinomas, lung carcinomas and sarcomas)  and not in normal tissues, with the exception of testis  and placenta (for a review, see reference <xref ref-type="bibr" rid="B15">15</xref>). CD8<sup>&#x0002b;</sup> CTLs  from melanoma patients recognize HLA class I&#x02013;restricted  MAGE-3 epitopes (<xref ref-type="bibr" rid="B15">15</xref>), and clinical trials with synthetic  peptides corresponding to HLA-A1 and/or -A2 MAGE-3  binding sequences are ongoing in patients affected by melanoma and other neoplastic diseases (<xref ref-type="bibr" rid="B15">15</xref>). Therefore, MAGE-3  is an excellent candidate protein to study the antitumor  CD4<sup>&#x0002b;</sup> T cell response. This protein has an intracytoplasmic  localization (<xref ref-type="bibr" rid="B16">16</xref>), making its presentation on MHC class II  molecules unlikely or difficult. However, it has been  clearly shown that the MHC class II pathway can present  endogenous cellular peptides (<xref ref-type="bibr" rid="B17">17</xref>&#x02013;<xref ref-type="bibr" rid="B19">19</xref>), and peptides eluted  from purified HLA-DR molecules of the melanoma cell  line FM3 contained peptides derived from processing of  cytoplasmic proteins (<xref ref-type="bibr" rid="B20">20</xref>).</p><p>In this study, we used a new T cell epitope prediction  software (TEPITOPE; reference <xref ref-type="bibr" rid="B21">21</xref>, and our manuscript  in preparation) to identify MAGE-3 sequences with promiscuous HLA-DR binding characteristics. Synthetic peptides corresponding to five identified sequences were used  to propagate CD4<sup>&#x0002b;</sup> T cells from the blood of a healthy  donor. We show that CD4<sup>&#x0002b;</sup> T cells are MAGE-3 specific and recognize naturally processed sequence segment(s). Moreover, CD4<sup>&#x0002b;</sup> T cells are cytolytic and recognize MAGE-3<sub>281&#x02013;295</sub> in association with HLA-DR11 on  melanoma cells.</p><sec id="MaterialsMethods" sec-type="materials|methods"><title>Materials and Methods</title><sec disp-level="3"><title>T Cell Epitope Prediction.</title><p>TEPITOPE, a new T cell epitope  prediction software, is a Windows&#x02122; application that enables the  identification of (a) class II ligands binding in a promiscuous or  allele-specific mode, and (b) the effects of polymorphic residues  on class II ligand specificity (21, and our manuscript in preparation). 25 quantitative matrix-based HLA-DR motifs, covering  the majority of class II ligand specificity, are incorporated in  TEPITOPE (22, and our manuscript in preparation) and provide  the basis for various algorithms included in the software package. Starting from any protein sequence, the algorithm permits  the prediction and parallel display of ligands for each of the 25  HLA-DR alleles. To predict MAGE-3 CD4<sup>&#x0002b;</sup> T cell epitopes, we  loaded the protein sequence into the software looking for promiscuous peptide regions. We set the TEPITOPE prediction  threshold at 5% (<xref ref-type="bibr" rid="B21">21</xref>) and picked peptide sequences predicted to  bind at least 50% of the HLA-DR molecules incorporated in the  software.</p></sec><sec disp-level="3"><title>DR&#x02013;Peptide Binding Assay.</title><p>Peptide interactions with detergent-solubilized DR molecules were measured using an ELISA-based high-flux competition assay (<xref ref-type="bibr" rid="B23">23</xref>). HLA-DR molecules  were isolated from the following human lymphoblastoid cell lines  (LCL): DR1 (DRB1*0101) from HOM-2, DR3 (DRB1*0301)  from WT49, DR4 (DRB1*0401) from PREISS, DR5 (DRB1*  1101) from SWEIG, DR7 (DRB1*0701) from EKR, and DR8  (DRB1*0801) from BM9. DR2 (DRB1*1501) was isolated from  the L cell transfectant L466.1. The molecules were affinity purified using the mAb 1-1C4 (<xref ref-type="bibr" rid="B24">24</xref>) as described (<xref ref-type="bibr" rid="B25">25</xref>). Peptide competition assays were conducted to measure the ability of unlabeled  peptides to compete with a biotinylated indicator peptide for  binding to purified DR molecules. The following biotinylated  indicator peptides were used: GFKA<sub>7</sub> for DR1 and DR7;  GIRA<sub>2</sub>YA<sub>4</sub> for DR2; LAYDA<sub>5</sub> for DR3; UD4 for DR4 (<xref ref-type="bibr" rid="B26">26</xref>);  TT 830&#x02013;843 for DR5; and GYRA<sub>6</sub>L for DR8. The biotinylated  indicator peptide and HLA-DR molecules were incubated with  10-fold dilutions (0.001&#x02013;100 mM) of the unlabeled competitor  peptides (peptides corresponding to the MAGE-3 predicted sequences). To determine relative peptide binding affinity, the promiscuous HA<sub>307&#x02013;319</sub> peptide from influenza hemagglutinin (<xref ref-type="bibr" rid="B27">27</xref>)  was included in each competition assay. The relative binding data  of the unlabeled competitor peptides were expressed as inhibitory  concentration (IC<sub>50</sub>), i.e., the concentration of competitor peptide required to inhibit 50% of binding of the biotinylated indicator peptide.</p></sec><sec disp-level="3"><title>Peptide Synthesis.</title><p>Synthetic peptides corresponding to MAGE-3<sub>141&#x02013;155</sub>, MAGE-3<sub>146&#x02013;160</sub>, MAGE-3<sub>156&#x02013;170</sub>, MAGE-3<sub>171&#x02013;185</sub>, and  MAGE-3<sub>281&#x02013;295</sub> sequences were manufactured on a 9050 <named-content content-type="company" xlink:href="millipore">Millipore</named-content> synthesizer. The purity of the peptides was evaluated by reverse-phase HPLC and electron spray mass spectrometry. Synthetic peptides were lyophilized and then reconstituted in DMSO  at 2 mg/ml concentration and diluted in PBS as needed.</p></sec><sec disp-level="3"><title>Cloning and Expression of rMAGE-3.</title><p>Full-length MAGE-3  coding sequences were inserted into expression vector pET16b  (Novagen), allowing the production of the NH<sub>2</sub> terminus 10-histidine tail as described (<xref ref-type="bibr" rid="B16">16</xref>). Production and purification of the recombinant fusion protein on nickel column were monitored by  SDS-PAGE and Coomassie blue staining.</p></sec><sec disp-level="3"><title>Propagation of CD4<sup>&#x0002b;</sup> T Cells.</title><p>The five synthetic peptides corresponding to the MAGE-3 sequences most promiscuous for  HLA-DR binding (see Table <xref ref-type="table" rid="TI">I</xref>) were pooled (hereafter MAGE-3  pool) and used to stimulate the PBMCs of a healthy donor whose  HLA type, identified by standard serologic typing, is A1, A2/ B41, B52/DR11, as described (<xref ref-type="bibr" rid="B28">28</xref>). In brief, 20 &#x000d7; 10<sup>6</sup> PBMCs  were cultivated for 7 d in RPMI 1640 (<named-content content-type="company" xlink:href="gibco">GIBCO BRL</named-content>) supplemented with 10% heat-inactivated human serum (Technogenetics), 2 mM <sc>l</sc>-glutamine, 100 U/ml penicillin, 50 &#x003bc;g/ml streptomycin (Biowhittaker) (TCM) containing the MAGE-3 pool (1  &#x003bc;g/ml of each peptide). The reactive lymphoblasts were isolated  on a Percoll gradient (<xref ref-type="bibr" rid="B28">28</xref>), further expanded in T cell growth factor (Lymphocult; Biotest Diagnostic Inc.), and restimulated at  weekly intervals with the same amount of antigen plus irradiated  (4,000 rad) autologous PBMCs as APCs. </p></sec><sec disp-level="3"><title>Flow Cytometry.</title><p>Cytofluorimetric analyses were performed  on a FACStarPlus<sup>&#x000ae;</sup> (<named-content content-type="company" xlink:href="becton">Becton Dickinson</named-content>). The following mAbs  were used: anti-CD4&#x02013;PE and anti-CD8&#x02013;FITC (<named-content content-type="company" xlink:href="becton">Becton Dickinson</named-content>), D1.12 (purified from an anti-MHC class II hybridoma supernatant), and 57B (described in reference <xref ref-type="bibr" rid="B16">16</xref>). FITC-rabbit  anti&#x02013;mouse Ig antibody (DAKO) was used as second-step reagent  in indirect immunofluorescence stainings. Staining for intracytoplasmic MAGE-3 expression was performed as described (<xref ref-type="bibr" rid="B29">29</xref>).  Intracytoplasmic staining for cytokine expression was performed  using the anti&#x02013;INF-&#x003b3; and anti&#x02013;IL-4 mAbs, following the manufacturer's instructions (<named-content content-type="company" xlink:href="sigma">Sigma</named-content>).</p></sec><sec disp-level="3"><title>Proliferation Assay.</title><p>CD4<sup>&#x0002b;</sup> T cells and autologous irradiated  PBMCs were diluted in TCM to 2 &#x000d7; 10<sup>5</sup>/ml and 2 &#x000d7; 10<sup>6</sup>/ml,  respectively, and plated in triplicate in 96 round-bottomed well  plates (100 &#x003bc;l of CD4<sup>&#x0002b;</sup> T cells and 100 &#x003bc;l of APCs). The cells  were stimulated with different concentrations of MAGE-3 pool  (0.05, 0.1, 0.5, 1, and 5 &#x003bc;g/ml), each peptide (10 &#x003bc;g/ml), and  different concentrations of rMAGE-3 protein (5, 10, and 20 &#x003bc;g/ ml). Triplicate wells with CD4<sup>&#x0002b;</sup> T cells alone and APCs alone  were used as controls. Three wells with CD4<sup>&#x0002b;</sup> T cells plus APCs  did not receive any stimulus in order to determine the basal  growth rate (the blank). In inhibition experiments, different concentrations of mAb L243 or an isotype-matched irrelevant mAb  (0.25 and 0.5 mg/ml) were added in triplicate wells of CD4<sup>&#x0002b;</sup>  cells plus APCs stimulated with MAGE-3 pool (5 &#x003bc;g/ml) or  MAGE-3<sub>281&#x02013;295</sub> (10 &#x003bc;g/ml). After 3 d, the cultures were pulsed  for 16 h with [<sup>3</sup>H]TdR (1 mCi/well, 6.7 Ci/mol; <named-content content-type="company" xlink:href="amersham">Amersham</named-content>  <named-content content-type="company" xlink:href="pharmacia">Pharmacia Biotech</named-content>). The cells were collected with a Titertek  multiple harvester (Skatron, Inc.), and the thymidine incorporated was measured in a liquid scintillation counter. The percentage of inhibition was calculated as follows: [(cpm without mAb &#x02212;  cpm with mAb)/(cpm without mAb)] &#x000d7; 100.</p></sec><sec disp-level="3"><title>Cytotoxicity Assay.</title><p>CD4<sup>&#x0002b;</sup> T cells were tested for specific lytic  activity in a standard 4-h <sup>51</sup>Cr-release assay as described (<xref ref-type="bibr" rid="B30">30</xref>). The  following targets were used: melanoma cells (SK-Mel 28,  HT144, OI TC described in reference <xref ref-type="bibr" rid="B29">29</xref>, and MD TC established in our laboratory from a cutaneous metastasis), and  LCL. The HLA-DR type of target cells, identified by molecular  or serologic typing, was SK-Mel 28 (DR*04*13), HT144  (DR*04*07), OI TC (DR*01*11), MD TC (DR*04*11), LCL  (DR11). In cold target competition assays, unlabeled target cells  (cold targets) were seeded in plates at serial ratios of hot-to-cold  target cells. Effector CD4<sup>&#x0002b;</sup> T cells and <sup>51</sup>Cr-labeled target cells  (hot targets) were then added, and cytotoxicity was assessed as described above. Percentage inhibition was calculated as follows:  [(% specific lysis without cold target &#x02212; % specific lysis with cold  target)/(% specific lysis without cold target)] &#x000d7; 100.</p></sec></sec><sec id="ResultsDiscussion"><title>Results and Discussion</title><p>10 synthetic peptides corresponding to sequence segments predicted by TEPITOPE to form promiscuous  MAGE-3 CD4<sup>&#x0002b;</sup> T cell epitopes were synthesized, and  their binding to purified molecules of 7 widely diffuse  HLA-DR alleles was verified. Based on the results of the  competition binding assays, 5 (i.e., the sequences with the  greatest degree of promiscuity) of the 10 predicted sequences were chosen for further experiments (Table <xref ref-type="table" rid="TI">I</xref>).  The five synthetic peptides were pooled (MAGE-3 pool)  and used to stimulate the PBMCs of a healthy donor. T  cells were 94% CD4<sup>&#x0002b;</sup> after 1 wk of culture (not shown),  and could be propagated in long-term culture by weekly  restimulation with the MAGE-3 pool in the presence of  autologous irradiated PBMCs. Reactivity of CD4<sup>&#x0002b;</sup> T cells  was tested in microproliferation assays (Fig. <xref ref-type="fig" rid="F1">1</xref>): the cells responded vigorously to the MAGE-3 pool (Fig. <xref ref-type="fig" rid="F1">1</xref> A), even  at low concentrations (100&#x02013;500 ng/ml). Reactivity to the  individual peptides forming the pool was also periodically  investigated (Fig. <xref ref-type="fig" rid="F1">1</xref> C): the CD4<sup>&#x0002b;</sup> T cells recognized predominantly the peptide corresponding to MAGE-3<sub>281&#x02013;295</sub>  and, although to a much lower but significant extent, the  peptides corresponding to the overlapping sequences  MAGE-3<sub>141&#x02013;155</sub> and MAGE-3<sub>146&#x02013;160</sub>. All three sequences  recognized by the CD4<sup>&#x0002b;</sup> T cells showed a high binding affinity to purified DR11 molecules (see Table <xref ref-type="table" rid="TI">I</xref>). Reactivity  to MAGE-3<sub>281&#x02013;295</sub> increased during the propagation of the  line (Fig. <xref ref-type="fig" rid="F1">1</xref> C). The proliferative activity of CD4<sup>&#x0002b;</sup> T cells  in the presence of MAGE-3 pool (Fig. <xref ref-type="fig" rid="F1">1</xref> D, a) or MAGE-3<sub>281&#x02013;295</sub> (Fig. <xref ref-type="fig" rid="F1">1</xref> D, b) was inhibited by addition in culture of  different concentrations of L243 mAb (Fig. <xref ref-type="fig" rid="F1">1</xref> D), demonstrating that the recognition of MAGE-3 sequences was  HLA-DR restricted. We next tested the CD4<sup>&#x0002b;</sup> T cells for  cross-reactivity with the native protein (Fig. <xref ref-type="fig" rid="F1">1</xref> B). CD4<sup>&#x0002b;</sup> T  cells strongly recognized the rMAGE-3 protein after processing and presentation by autologous APCs, demonstrating that the synthetic sequences recognized by the CD4<sup>&#x0002b;</sup> T  cells indeed formed naturally processed epitopes. </p><p>Intracytoplasmic staining for IL-4 and INF-&#x003b3; expression,  performed after CD4<sup>&#x0002b;</sup> T cell activation with PMA and  ionomycin, revealed that 70% of the CD4<sup>&#x0002b;</sup> T cells produced INF-&#x003b3; while no cells produced IL-4 (data not  shown), suggesting that they belong mostly to the Th1  type.</p><p>To characterize the functional activity of the MAGE-3&#x02013; specific CD4<sup>&#x0002b;</sup> T cells, we tested their killing potential  against melanoma cells expressing the MAGE-3 protein  and the HLA-DR molecules (Fig. <xref ref-type="fig" rid="F2">2</xref> B). CD4<sup>&#x0002b;</sup> T cells  showed cytolytic activity against OI TC and MD TC,  which express the HLA-DR11 restricting allele, whereas  they did not kill SK-Mel 28 and HT144, which express  unrelated HLA-DR alleles (Fig. <xref ref-type="fig" rid="F2">2</xref> A). To verify whether  the cytolytic CD4<sup>&#x0002b;</sup> T cells recognized HLA-DR11&#x02013; restricted MAGE-3 epitopes on melanoma cells, we first  tested their lytic activity against HLA-DR11<sup>&#x0002b;</sup> LCL unpulsed, or pulsed with the synthetic peptides recognized in  microproliferation assays. LCL pulsed with MAGE-3<sub>281&#x02013;295</sub>  were strongly recognized by the CD4<sup>&#x0002b;</sup> T cells, whereas  no killing activity against LCL unpulsed or pulsed with  MAGE-3<sub>141&#x02013;155</sub> and MAGE-3<sub>146&#x02013;160</sub> was detectable (Fig. <xref ref-type="fig" rid="F3">3</xref>  A). Second, we performed cold target inhibition experiments which showed that the lytic activity of CD4<sup>&#x0002b;</sup> T cells  against OI TC was inhibited by the addition of LCL pulsed  with MAGE-3<sub>281&#x02013;295 </sub>(Fig. <xref ref-type="fig" rid="F3">3</xref> B), demonstrating that this sequence is indeed presented by HLA-DR11 on the OI TC  melanoma cells. These results further demonstrate that  MAGE-3<sub>281&#x02013;295</sub> is naturally processed and forms a cytotoxic  CD4<sup>&#x0002b;</sup> T cell epitope. Since the polyclonal CD4<sup>&#x0002b;</sup> T cells  proliferated in the presence of the rMAGE-3 protein, and in  addition to MAGE-3<sub>281&#x02013;295</sub> they also recognized MAGE-3<sub>141&#x02013;155</sub> and MAGE-3<sub>146&#x02013;160</sub>, we cannot exclude that these  last two sequences may also yield natural epitopes, which are  recognized by CD4<sup>&#x0002b;</sup> T cells with functional activity different from killing. Moreover, although CD4<sup>&#x0002b;</sup> T cells were  mostly Th1 and had direct effector function upon tumor  recognition, we cannot exclude that in vivo such CD4<sup>&#x0002b;</sup> T  cells could also exert a helper activity in the induction  phase of the immune response.  </p><p>One approach for identifying CD4<sup>&#x0002b;</sup> T cell epitopes on a  candidate protein is the use of overlapping synthetic peptides corresponding to the complete sequence of the protein. The major drawback of this approach is the number  of peptide sequences that need to be tested, thus making  this approach too expensive and time consuming. In this  study, we used the TEPITOPE software package to computationally identify promiscuous HLA-DR binding sites  starting from primary protein structures. We demonstrated  that TEPITOPE predicted sequence segments capable of  binding to multiple HLA-DR alleles. Furthermore, we  showed that one or more of the predicted HLA-DR  ligands were indeed naturally processed, thus confirming  the validity of this approach. We expect that the application of TEPITOPE to other tumor-associated antigens will  speed up identification of the antitumor CD4<sup>&#x0002b;</sup> T cell  epitope repertoire in humans.</p><p>Clinical trials based on the use of melanocyte-specific  antigens (such as gp100, MART-1/Melan-A, and tyrosinase, for which CD4<sup>&#x0002b;</sup> T cell epitopes were identified) are  in progress in melanoma patients, and although no significant side effects were reported in a recent study that used a  gp100 peptide for the treatment of HLA-A2<sup>&#x0002b;</sup> patients (<xref ref-type="bibr" rid="B31">31</xref>),  the development of autoimmune responses against normal  tissue must be considered when using self-differentiation  antigens as vaccines. The demonstration that MAGE-3  (i.e., an antigen not expressed in normal tissues, with the  exception of testis and placenta, which are unlikely to be  targets of T cells since they do not express MHC molecules), can form CD4<sup>&#x0002b;</sup> T cell epitopes further supports its  use for vaccination protocols in neoplastic patients using a  mixture of synthetic peptides corresponding to CD8<sup>&#x0002b;</sup> and  CD4<sup>&#x0002b;</sup> T cell epitopes.</p><p>Previous findings (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>) reported a lytic activity of  melanoma-specific CD4<sup>&#x0002b;</sup> T cells. Here we give the molecular definition of an epitope able to stimulate cytolytic CD4<sup>&#x0002b;</sup>  T cells that can be grown in vitro with ease, raising the possibility of using those CD4<sup>&#x0002b;</sup> T cells in protocols of adoptive  transfer in neoplastic patients whose neoplasm expresses the  MAGE-3 protein and the MHC class II molecules.</p><p>In conclusion, in this study we identified the first CD4<sup>&#x0002b;</sup> T  cell epitope on a tumor-specific antigen, and we verified that  the approach used here to predict promiscuous CD4<sup>&#x0002b;</sup> T cell  epitopes yielded natural epitopes. It will be important to  evaluate whether the identified CD4<sup>&#x0002b;</sup> T cell epitopes are indeed promiscuous, making their use for peptide-based vaccines less allele dependent and more widely applicable.</p></sec></body><back><sec sec-type="display-objects"><title>Figures and Tables</title><table-wrap position="float" id="TI"><label>Table I</label><caption><p>Determination of HLA-DR Binding of MAGE-3 Synthetic Peptides Corresponding to Sequences Predicted to Form Promiscuous Epitopes </p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Residues</th><th rowspan="2"/><th rowspan="2">Sequence</th><th rowspan="2"/><th colspan="13">HLA-DR alleles</th></tr><tr><th>*0101</th><th/><th>*0301</th><th/><th>*0401</th><th/><th>*0701</th><th/><th>*0801</th><th/><th>*1101</th><th/><th>*1501</th></tr></thead><tbody><tr><td align="left">141&#x02013;155</td><td align="left"/><td align="left">GNWQYFFPVIFSKAS</td><td align="left"/><td align="left">&#x02009;&#x02009;&#x02009;25</td><td align="left"/><td align="left">&#x0003e;100<xref ref-type="table-fn" rid="TFI-152">&#x02021;</xref></td><td align="left"/><td align="left">&#x02009;&#x02009;&#x02009;&#x000a0;7</td><td align="left"/><td align="left">&#x02009;&#x02009;&#x02009;&#x02009;0.1</td><td align="left"/><td align="left">&#x02009;&#x02009;&#x02009;&#x02009;3.2</td><td align="left"/><td align="left">&#x000a0;&#x02009;0.6</td><td align="left"/><td align="left">&#x02009;&#x02009;&#x02009;3</td></tr><tr><td align="left">146&#x02013;160</td><td align="left"/><td align="left">FFPVIFSKASSSLQL</td><td align="left"/><td align="left">&#x02009;&#x02009;&#x02009;10</td><td align="left"/><td>&#x000a0;&#x02009;&#x02009;&#x02009;&#x02009;7</td><td align="left"/><td align="left">&#x000a0;&#x02009;&#x02009;&#x02009;2</td><td align="left"/><td>0.01</td><td align="left"/><td align="left">&#x02009;&#x02009;&#x02009;&#x02009;1.5</td><td align="left"/><td align="left">&#x000a0;&#x02009;1.8</td><td align="left"/><td align="left">&#x02009;&#x02009;&#x02009;0.2</td></tr><tr><td align="left">156&#x02013;170</td><td/><td align="left">SSLQLVFGIELMEVD</td><td/><td align="left">&#x02009;&#x02009;&#x02009;&#x000a0;7</td><td/><td>&#x02009;&#x02009;&#x02009;90</td><td/><td align="left">&#x02009;&#x02009;&#x02009;45</td><td/><td>0.03</td><td/><td align="left">&#x02009;&#x02009;&#x02009;&#x02009;7</td><td/><td align="left">28</td><td/><td>0.18</td></tr><tr><td align="left">171&#x02013;185</td><td/><td align="left">PIGHLYIFATCLGLS</td><td/><td>0.3</td><td/><td>&#x000a0;&#x000a0;&#x02009;&#x02009;&#x02009;&#x02009;&#x02009;&#x02009;2.8</td><td/><td>&#x000a0;0.9</td><td/><td>0.01</td><td/><td align="left">&#x02009;&#x02009;&#x02009;&#x02009;1.5</td><td/><td align="left">&#x000a0;&#x02009;0.9</td><td/><td>0.03</td></tr><tr><td align="left">281&#x02013;295</td><td align="left"/><td align="left">TSYVKVLHHMVKISG</td><td align="left"/><td align="left">&#x02009;&#x02009;&#x02009;15</td><td align="left"/><td>&#x02009;&#x02009;&#x02009;26</td><td align="left"/><td align="left">&#x02009;&#x02009;&#x02009;&#x02009;70</td><td align="left"/><td>0.02</td><td align="left"/><td>0.01</td><td align="left"/><td>&#x000a0;0.03</td><td align="left"/><td align="left">&#x02009;&#x02009;&#x02009;&#x02009;0.5</td></tr></tbody></table><table-wrap-foot><fn><p>The binding data are expressed in terms of relative binding capacity (IC<sub>50</sub> &#x003bc;M), calculated as concentration of competitor peptide required to inhibit  50% of the binding of an allele-specific biotinylated peptide (indicator peptide).  &#x000a0;</p></fn><fn id="TFI-152"><label>&#x02021;</label><p>&#x02009;IC<sub>50</sub> values &#x0003e;100 &#x003bc;M are outside the sensitivity limits of the binding assay.                &#x000a0;</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F1"><label>Figure 1</label><caption><p>Proliferative activity of CD4<sup>&#x0002b;</sup> T cells stimulated with  MAGE-3 pool measured in 2-d microproliferation assays. The data are  representative of <italic>n</italic> &#x0003d; <italic>x</italic> experiments, and are means of triplicate determinations &#x000b1; SD. (A) Responses to MAGE-3 pool (0.01, 0.5, 0.1, 0.5, 1, and 5  &#x003bc;g/ml; <italic>n</italic> &#x0003d; 6). (B) Responses to rMAGE-3 protein (5, 10, and 20 &#x003bc;g/ml;  <italic>n</italic> &#x0003d; 3). (C) Responses to the individual synthetic peptides forming the  MAGE-3 pool (10 &#x003bc;g/ml; <italic>n</italic> &#x0003d; 7) at different weeks of propagation. The  blank (i.e., the basal level of proliferation of CD4<sup>&#x0002b;</sup> T cells in the presence  of APCs only) was subtracted and was as follows: 2 wk, 30,866 &#x000b1; 1,115;  4 wk, 7,106 &#x000b1; 2,201; and 6 wk, 21,838 &#x000b1; 2,767. Responses significantly  higher than the blanks are indicated as *<italic>P</italic> &#x0003c; 0.001 and **<italic>P</italic> &#x0003c; 0.025 (determined by unpaired, one-tailed Student's <italic>t</italic> test). (D) Response to MAGE-3  pool (5 &#x003bc;g/ml; <italic>n</italic> &#x0003d; 5) (a) and to peptide corresponding to sequence  281&#x02013;295 (b), in the presence of different doses of L243 mAb (0.25 and 0.5  &#x003bc;g/ml). The blank was 1,251 &#x000b1; 444; the proliferation of CD4<sup>&#x0002b;</sup> T cells in  the presence of MAGE-3 pool was 28,191 &#x000b1; 373; and the proliferation in  the presence of sequence 281&#x02013;295 was 22,504 &#x000b1; 141.</p></caption><graphic xlink:href="JEM981989.f1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Cytolytic activity of  MAGE-3&#x02013;specific CD4<sup>&#x0002b;</sup> T cells.  The data are representative of <italic>n</italic> &#x0003d; <italic>x</italic>  experiments, and are means of  triplicate determinations &#x000b1; SD.  (A) Lytic activity against different  HLA-DR&#x02013;matched and unmatched melanoma cells (<italic>n</italic> &#x0003d; 6).  HLA-DR types of CD4<sup>&#x0002b;</sup> T cells  and melanomas are indicated at the  bottom along with their symbols.  (B) Cytofluorimetric analysis for  HLA-DR (surface) and MAGE-3  (intracytoplasmic) expression in  melanoma cells used as targets (<italic>n</italic> &#x0003d;  4). Filled histograms, stained sample; open histograms, background  staining obtained with FITC-conjugated second-step reagent only.</p></caption><graphic xlink:href="JEM981989.f2a"/><graphic xlink:href="JEM981989.f2b"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>CD4<sup>&#x0002b;</sup> T cells recognize MAGE-3<sub>281&#x02013;295</sub> in association with  HLA-DR11 on OI TC cells. The data are representative of <italic>n</italic> &#x0003d; <italic>x</italic> experiments, and are means of triplicate determinations &#x000b1; SD. (A) Lytic activity of CD4<sup>&#x0002b;</sup> CTLs against LCL alone or LCL pulsed with MAGE-3<sub>141&#x02013;155</sub>, MAGE-3<sub>146&#x02013;160</sub>, and MAGE-3<sub>281&#x02013;295 </sub>(<italic>n</italic> &#x0003d; 3). (B) Cold target  inhibition experiments (<italic>n</italic> &#x0003d; 3). Cold targets (OI TC [&#x025cb;] and LCL pulsed  with MAGE-3<sub>281&#x02013;295</sub> [&#x025a1;]) were used to inhibit the lytic activity of  MAGE-3&#x02013;specific CD4<sup>&#x0002b;</sup> CTLs against hot OI TC (E/T ratio of 40:1).  Percentage of specific lysis against OI TC cells in the absence of cold targets was 26 &#x000b1; 1.2%.</p></caption><graphic xlink:href="JEM981989.f3"/></fig></sec><ack><p>We thank Giuseppe Consogno for excellent technical support and Catia Traversari for critical reading of the  manuscript and helpful discussions.</p><p>This work was supported by the Fondazione Centro San Raffaele del Monte Tabor, the Italian Association  for Cancer Research (AIRC), the Ministry of University and Scientific Research (MURST), and the Swiss  National Fund.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>PD</given-names></name></person-group><article-title>Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells</article-title><source>Adv Immunol</source><year>1991</year><volume>49</volume><fpage>281</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">1853786</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Aanathaswamy</surname><given-names>H</given-names></name></person-group><article-title>Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2</article-title><source>J  Immunol</source><year>1993</year><volume>151</volume><fpage>244</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">8326126</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mandelboim</surname><given-names>O</given-names></name><name><surname>Vadai</surname><given-names>E</given-names></name><name><surname>Fridkin</surname><given-names>M</given-names></name><name><surname>Katz-Hillel</surname><given-names>A</given-names></name><name><surname>Feldman</surname><given-names>M</given-names></name><name><surname>Berke</surname><given-names>G</given-names></name><name><surname>Eisenbach</surname><given-names>L</given-names></name></person-group><article-title>Regression of established murine carcinoma metastases following vaccination with tumor-associated antigen peptides</article-title><source>Nat Med</source><year>1995</year><volume>1</volume><fpage>1179</fpage><lpage>1183</lpage><pub-id pub-id-type="pmid">7584991</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mayordomo</surname><given-names>JI</given-names></name><name><surname>Zorina</surname><given-names>T</given-names></name><name><surname>Storkus</surname><given-names>WJ</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Celluzzi</surname><given-names>C</given-names></name><name><surname>Falo</surname><given-names>LD</given-names></name><name><surname>Melief</surname><given-names>CJM</given-names></name><name><surname>Ildstad</surname><given-names>ST</given-names></name><name><surname>Kast</surname><given-names>WM</given-names></name><name><surname>Deleo</surname><given-names>AB</given-names></name><name><surname>Lotze</surname><given-names>MT</given-names></name></person-group><article-title>Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity</article-title><source>Nat Med</source><year>1995</year><volume>1</volume><fpage>1297</fpage><lpage>1302</lpage><pub-id pub-id-type="pmid">7489412</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bellone</surname><given-names>M</given-names></name><name><surname>Iezzi</surname><given-names>G</given-names></name><name><surname>Martin-Fontecha</surname><given-names>A</given-names></name><name><surname>Rivolta</surname><given-names>L</given-names></name><name><surname>Manfredi</surname><given-names>AA</given-names></name><name><surname>Protti</surname><given-names>MP</given-names></name><name><surname>Freschi</surname><given-names>M</given-names></name><name><surname>Dellabona</surname><given-names>P</given-names></name><name><surname>Casorati</surname><given-names>G</given-names></name><name><surname>Rugarli</surname><given-names>C</given-names></name></person-group><article-title>Rejection of a non-immunogenic melanoma by vaccination with natural melanoma peptides on engineered APC</article-title><source>J Immunol</source><year>1997</year><volume>158</volume><fpage>783</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">8992995</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ostrand-Rosemberg</surname><given-names>S</given-names></name><name><surname>Thakur</surname><given-names>A</given-names></name><name><surname>Clements</surname><given-names>V</given-names></name></person-group><article-title>Rejection of mouse sarcoma cells after transfection of MHC class II genes</article-title><source>J Immunol</source><year>1990</year><volume>144</volume><fpage>4068</fpage><lpage>4071</lpage><pub-id pub-id-type="pmid">2332639</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>R</given-names></name><name><surname>Edwards</surname><given-names>S</given-names></name><name><surname>Hui</surname><given-names>K</given-names></name><name><surname>Bassett</surname><given-names>P</given-names></name><name><surname>Grosveld</surname><given-names>F</given-names></name></person-group><article-title>The effect of class II gene transfection on the tumorigenicity of the H-2K negative mouse leukemia cell line K36.16</article-title><source>Immunology</source><year>1991</year><volume>72</volume><fpage>213</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">1901830</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ossendorp</surname><given-names>F</given-names></name><name><surname>Menged&#x000e9;</surname><given-names>E</given-names></name><name><surname>Camps</surname><given-names>M</given-names></name><name><surname>Filius</surname><given-names>R</given-names></name><name><surname>Melief</surname><given-names>CJM</given-names></name></person-group><article-title>Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors</article-title><source>J Exp  Med</source><year>1998</year><volume>187</volume><fpage>693</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">9480979</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goedegebuure</surname><given-names>PS</given-names></name><name><surname>Eberlein</surname><given-names>TJ</given-names></name></person-group><article-title>The role of  CD4<sup>&#x0002b;</sup>tumor-infiltrating lymphocytes in human solid tumors</article-title><source>Immunol Res</source><year>1995</year><volume>14</volume><fpage>119</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">8530876</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maccalli</surname><given-names>C</given-names></name><name><surname>Mortarini</surname><given-names>R</given-names></name><name><surname>Parmiani</surname><given-names>G</given-names></name><name><surname>Anichini</surname><given-names>A</given-names></name></person-group><article-title>Multiple sub-set of CD4<sup>&#x0002b;</sup> and CD8<sup>&#x0002b;</sup>cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles</article-title><source>Int J Cancer</source><year>1994</year><volume>57</volume><fpage>56</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">7908659</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sahin</surname><given-names>U</given-names></name><name><surname>Tureci</surname><given-names>O</given-names></name><name><surname>Pfreundschuh</surname><given-names>M</given-names></name></person-group><article-title>Serological identification of human tumor antigens</article-title><source>Curr Opin Immunol</source><year>1997</year><volume>9</volume><fpage>709</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">9368781</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Rivoltini</surname><given-names>L</given-names></name><name><surname>Mancini</surname><given-names>M</given-names></name><name><surname>Markus</surname><given-names>NR</given-names></name><name><surname>Robbins</surname><given-names>PF</given-names></name><name><surname>Kawakami</surname><given-names>Y</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><article-title>Human  CD4<sup>&#x0002b;</sup>T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene</article-title><source>Proc Natl  Acad Sci USA</source><year>1994</year><volume>91</volume><fpage>9461</fpage><lpage>9465</lpage><pub-id pub-id-type="pmid">7937789</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yee</surname><given-names>C</given-names></name><name><surname>Gilbert</surname><given-names>MJ</given-names></name><name><surname>Riddell</surname><given-names>SR</given-names></name><name><surname>Brichard</surname><given-names>VG</given-names></name><name><surname>Fefer</surname><given-names>A</given-names></name><name><surname>Thompson</surname><given-names>JA</given-names></name><name><surname>Boon</surname><given-names>T</given-names></name><name><surname>Greenberg</surname><given-names>PD</given-names></name></person-group><article-title>Isolation of tyrosinase-specific CD8<sup>&#x0002b;</sup> and CD4<sup>&#x0002b;</sup>T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus</article-title><source>J Immunol</source><year>1996</year><volume>157</volume><fpage>4079</fpage><lpage>4086</lpage><pub-id pub-id-type="pmid">8892642</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Gonzales</surname><given-names>MI</given-names></name><name><surname>Parkhurst</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>YF</given-names></name><name><surname>Southwood</surname><given-names>S</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Robbins</surname><given-names>PF</given-names></name></person-group><article-title>Melanoma-specific CD4<sup>&#x0002b;</sup>T cells recognize nonmutated HLA-DR&#x02013;restricted tyrosinase epitopes</article-title><source>J Exp Med</source><year>1996</year><volume>183</volume><fpage>1965</fpage><lpage>1971</lpage><pub-id pub-id-type="pmid">8642306</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van den Eynde</surname><given-names>BJ</given-names></name><name><surname>van der Bruggen</surname><given-names>P</given-names></name></person-group><article-title>T cell defined tumor antigens</article-title><source>Immunol Today</source><year>1997</year><volume>9</volume><fpage>684</fpage><lpage>693</lpage></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kocher</surname><given-names>T</given-names></name><name><surname>Schultz-Tjater</surname><given-names>E</given-names></name><name><surname>Gudat</surname><given-names>F</given-names></name><name><surname>Schaefer</surname><given-names>C</given-names></name><name><surname>Casorati</surname><given-names>G</given-names></name><name><surname>Juretic</surname><given-names>A</given-names></name><name><surname>Willimann</surname><given-names>T</given-names></name><name><surname>Harder</surname><given-names>F</given-names></name><name><surname>Heberer</surname><given-names>M</given-names></name><name><surname>Spagnoli</surname><given-names>G</given-names></name></person-group><article-title>Identification and intracellular location of MAGE-3 gene product</article-title><source>Cancer Res</source><year>1995</year><volume>55</volume><fpage>2236</fpage><lpage>2239</lpage><pub-id pub-id-type="pmid">7757970</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nuchtern</surname><given-names>JG</given-names></name><name><surname>Biddison</surname><given-names>WE</given-names></name><name><surname>Klausner</surname><given-names>RD</given-names></name></person-group><article-title>Class II MHC molecules can use the endogenous pathway of antigen presentation</article-title><source>Nature</source><year>1990</year><volume>343</volume><fpage>74</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">1967486</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>BP</given-names></name><name><surname>Madrigal</surname><given-names>A</given-names></name><name><surname>Parham</surname><given-names>P</given-names></name></person-group><article-title>Cytotoxic T cell recognition of an endogenous class I HLA peptide presented by a class II HLA molecule</article-title><source>J Exp Med</source><year>1990</year><volume>172</volume><fpage>779</fpage><lpage>788</lpage><pub-id pub-id-type="pmid">2117634</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chicz</surname><given-names>RM</given-names></name><name><surname>Urban</surname><given-names>RG</given-names></name><name><surname>Gorga</surname><given-names>JC</given-names></name><name><surname>Vignali</surname><given-names>DA</given-names></name><name><surname>Lane</surname><given-names>WS</given-names></name><name><surname>Strominger</surname><given-names>JL</given-names></name></person-group><article-title>Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles</article-title><source>J Exp Med</source><year>1993</year><volume>178</volume><fpage>27</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">8315383</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halder</surname><given-names>T</given-names></name><name><surname>Pawelec</surname><given-names>G</given-names></name><name><surname>Kirkin</surname><given-names>AF</given-names></name><name><surname>Zeuthen</surname><given-names>J</given-names></name><name><surname>Meyer</surname><given-names>HE</given-names></name><name><surname>Kun</surname><given-names>L</given-names></name><name><surname>Kalbacher</surname><given-names>H</given-names></name></person-group><article-title>Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3</article-title><source>Cancer Res</source><year>1997</year><volume>57</volume><fpage>3228</fpage><lpage>3244</lpage></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hammer</surname><given-names>J</given-names></name><name><surname>Sturniolo</surname><given-names>T</given-names></name><name><surname>Sinigaglia</surname><given-names>F</given-names></name></person-group><article-title>HLA class II binding specificity and autoimmunity</article-title><source>Adv Immunol</source><year>1997</year><volume>66</volume><fpage>67</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">9328640</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hammer</surname><given-names>J</given-names></name><name><surname>Bono</surname><given-names>E</given-names></name><name><surname>Gallazzi</surname><given-names>F</given-names></name><name><surname>Belunis</surname><given-names>C</given-names></name><name><surname>Nagy</surname><given-names>ZA</given-names></name><name><surname>Sinigaglia</surname><given-names>F</given-names></name></person-group><article-title>Precise prediction of major histocompatibility complex class II&#x02013;peptide interaction based on peptide side chain scanning</article-title><source>J Exp Med</source><year>1994</year><volume>180</volume><fpage>2353</fpage><lpage>2358</lpage><pub-id pub-id-type="pmid">7964508</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raddrizzani</surname><given-names>L</given-names></name><name><surname>Sturniolo</surname><given-names>T</given-names></name><name><surname>Guenot</surname><given-names>J</given-names></name><name><surname>Bono</surname><given-names>E</given-names></name><name><surname>Gallazzi</surname><given-names>F</given-names></name><name><surname>Nagy</surname><given-names>ZA</given-names></name><name><surname>Sinigaglia</surname><given-names>F</given-names></name><name><surname>Hammer</surname><given-names>J</given-names></name></person-group><article-title>Different modes of peptide interaction enable HLA-DQ and HLA-DR molecules to bind diverse peptide repertoires</article-title><source>J  Immunol</source><year>1997</year><volume>159</volume><fpage>703</fpage><lpage>711</lpage><pub-id pub-id-type="pmid">9218585</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cammarota</surname><given-names>G</given-names></name><name><surname>Scheirle</surname><given-names>A</given-names></name><name><surname>Takacs</surname><given-names>B</given-names></name><name><surname>Doran</surname><given-names>DM</given-names></name><name><surname>Knorr</surname><given-names>R</given-names></name><name><surname>Bannwarth</surname><given-names>W</given-names></name><name><surname>Guardiola</surname><given-names>J</given-names></name><name><surname>Sinigaglia</surname><given-names>F</given-names></name></person-group><article-title>Identification of a CD4 binding site on the &#x003b2;2 domain of HLA-DR molecules</article-title><source>Nature</source><year>1992</year><volume>356</volume><fpage>799</fpage><lpage>801</lpage><pub-id pub-id-type="pmid">1574119</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sinigaglia</surname><given-names>F</given-names></name><name><surname>Romagnoli</surname><given-names>P</given-names></name><name><surname>Guttinger</surname><given-names>M</given-names></name><name><surname>Takacs</surname><given-names>B</given-names></name><name><surname>Pink</surname><given-names>JRL</given-names></name></person-group><article-title>Selection of T-cell epitopes and vaccine engineering</article-title><source>Methods Enzymol</source><year>1992</year><volume>203</volume><fpage>370</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">1722274</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hammer</surname><given-names>J</given-names></name><name><surname>Gallazzi</surname><given-names>F</given-names></name><name><surname>Bono</surname><given-names>E</given-names></name><name><surname>Karr</surname><given-names>RW</given-names></name><name><surname>Guenot</surname><given-names>J</given-names></name><name><surname>Valsasnini</surname><given-names>P</given-names></name><name><surname>Nagy</surname><given-names>ZA</given-names></name><name><surname>Sinigaglia</surname><given-names>F</given-names></name></person-group><article-title>Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association</article-title><source>J Exp Med</source><year>1995</year><volume>181</volume><fpage>1847</fpage><lpage>1855</lpage><pub-id pub-id-type="pmid">7722459</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roche</surname><given-names>PA</given-names></name><name><surname>Cresswell</surname><given-names>P</given-names></name></person-group><article-title>High-affinity binding of an influenza hemagglutinin-derived peptide to purified HLA-DR</article-title><source>J Immunol</source><year>1990</year><volume>144</volume><fpage>1849</fpage><lpage>1856</lpage><pub-id pub-id-type="pmid">2307844</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Protti</surname><given-names>MP</given-names></name><name><surname>Manfredi</surname><given-names>AA</given-names></name><name><surname>Straub</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Howard</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>Conti-Tronconi</surname><given-names>BM</given-names></name></person-group><article-title>Use of synthetic peptides to establish anti-human acetylcholine receptor CD4<sup>&#x0002b;</sup>cell lines from myasthenia gravis patients</article-title><source>J Immunol</source><year>1990</year><volume>144</volume><fpage>1711</fpage><lpage>1720</lpage><pub-id pub-id-type="pmid">1968487</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Imro</surname><given-names>MA</given-names></name><name><surname>Dellabona</surname><given-names>P</given-names></name><name><surname>Manici</surname><given-names>S</given-names></name><name><surname>Heltai</surname><given-names>S</given-names></name><name><surname>Consogno</surname><given-names>G</given-names></name><name><surname>Bellone</surname><given-names>M</given-names></name><name><surname>Rugarli</surname><given-names>C</given-names></name><name><surname>Protti</surname><given-names>MP</given-names></name></person-group><article-title>Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8<sup>&#x0002b;</sup>cytotoxic T lymphocytes in vitro</article-title><source>Hum Gene Ther</source><year>1998</year><volume>9</volume><fpage>1335</fpage><lpage>1344</lpage><pub-id pub-id-type="pmid">9650618</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Protti</surname><given-names>MP</given-names></name><name><surname>Imro</surname><given-names>MA</given-names></name><name><surname>Manfredi</surname><given-names>AA</given-names></name><name><surname>Consogno</surname><given-names>G</given-names></name><name><surname>Heltai</surname><given-names>S</given-names></name><name><surname>Arcelloni</surname><given-names>C</given-names></name><name><surname>Bellone</surname><given-names>M</given-names></name><name><surname>Dellabona</surname><given-names>P</given-names></name><name><surname>Casorati</surname><given-names>G</given-names></name><name><surname>Rugarli</surname><given-names>C</given-names></name></person-group><article-title>Particulate naturally processed peptides prime a cytotoxic response against human melanoma in vitro</article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><fpage>1210</fpage><lpage>1213</lpage><pub-id pub-id-type="pmid">8640799</pub-id></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Schwartzentruber</surname><given-names>DJ</given-names></name><name><surname>Hwu</surname><given-names>P</given-names></name><name><surname>Marincola</surname><given-names>FM</given-names></name><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name><name><surname>Schwarz</surname><given-names>SL</given-names></name><name><surname>Spiess</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma</article-title><source>Nat Med</source><year>1998</year><volume>4</volume><fpage>321</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">9500606</pub-id></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>WD</given-names></name><name><surname>Hersey</surname><given-names>P</given-names></name></person-group><article-title>CD4 T cells kill melanoma cells by mechanisms that are independent of FAS (CD95)</article-title><source>Int J Cancer</source><year>1998</year><volume>75</volume><fpage>384</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">9455798</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Chapman</surname><given-names>PB</given-names></name><name><surname>Yang</surname><given-names>SY</given-names></name><name><surname>Hara</surname><given-names>I</given-names></name><name><surname>Vijiayasaradhi</surname><given-names>S</given-names></name><name><surname>Houghton</surname><given-names>AN</given-names></name></person-group><article-title>Reactivity of autologous CD4<sup>&#x0002b;</sup>T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15</article-title><source>J Immunol</source><year>1995</year><volume>154</volume><fpage>772</fpage><lpage>779</lpage><pub-id pub-id-type="pmid">7814883</pub-id></citation></ref></ref-list></back></article>


